Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 1
Submit an article Journal homepage
56
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Ferric citrate: a novel phosphate-binding agent

Kausik Umanath Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA; Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
,
Robert Niecestro Independent Consultant, Pocono Pines, PA, USA; Independent Consultant, Pocono Pines, PA, USA
,
Julia B Lewis Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA
&
Jamie P Dwyer Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA. [email protected]
Pages 13-19 | Published online: 10 Jan 2014

References

  • Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. 73, S14–S19 (1999).
  • Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15(8), 2208–2218 (2004).
  • Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(4 Suppl. 3), S1–S201 (2003).
  • Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 113, S1–S130 (2009).
  • Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif. 23(Suppl. 1), 2–11 (2005).
  • Clarkson EM, Durrant C, Phillips ME, Gower PE, Jewkes RF, de Wardener HE. The effect of a high intake of calcium and phosphate in normal subjects and patients with chronic renal failure. Clin. Sci. 39(6), 693–704 (1970).
  • Clarkson EM, Eastwood JB, Koutsaimanis KG, de Wardener HE. Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. 3(4), 258–263 (1973).
  • Clarkson EM, McDonald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin. Sci. 30(3), 425–438 (1966).
  • Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. 29(4), 641–649 (1997).
  • McDonald SJ, Clarkson EM, Dewardener HE. The effect of a large intake of calcium citrate in normal subjects and patients with chronic renal failure. Clin. Sci. 26, 27–39 (1964).
  • How PP, Fischer JH, Arruda JA, Lau AH. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin. J. Am. Soc. Nephrol. 2(6), 1235–1240 (2007).
  • Feng L, Xiao H, He X et al. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol. Lett. 165(2), 112–120 (2006).
  • Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 68(6), 2809–2813 (2005).
  • [No authors listed]. Sevelamer reduces the efficacy of many other drugs. Prescrire. Int. 18(102), 164–165 (2009).
  • Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am. J. Kidney Dis. 42(6), 1253–1259 (2003).
  • Liu SH, Chu HI, Hsu HC, Chao HC, Cheu SH. Calcium and phosphorus metabolism in osteomalacia. XI. the pathogenetic role of pregnancy and relative importance of calcium and vitamin D supply. J. Clin. Invest. 20(3), 255–271 (1941).
  • Liu SH, Chu HI. Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T. 10) and iron. Medicine (Baltimore) 22, 103–161 (1943).
  • Fleming RE, Ponka P. Iron overload in human disease. N. Engl. J. Med. 366(4), 348–359 (2012).
  • Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol. Dial. Transplant. 17(2), 265–270 (2002).
  • Sinsakul MV, Korbet S, Greene T et al. The safety and tolerability of higher doses of ferric citrate in controlling serum phosphorus in ESRD patients. Poster Presented at: National Kidney Foundation Meetings. Orlando, FL, USA (2010).
  • II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am. J. Kidney Dis. 47(5 Suppl. 3), S16–S85 (2006).
  • Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am. J. Kidney Dis. 50(3), 471–530 (2007).
  • Sika M, Smith M, Schulman G, Kaplan M, Lewis JB. A dose-ranging and efficacy Phase 3 trial of ferric citrate (FC) as a phosphate binder in dialysis patients. Am. J. Kid. Dis. (2011) (Abstract 292).
  • Umanath K, Sika M, Niecestro RM et al. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial. Int. doi:10.1111/j.1542-4758.2012.00711.x (2012) (Epub ahead of print).
  • Finn WF; SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin. Nephrol. 65(3), 191–202 (2006).
  • Joy MS, Finn WF; LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. 42(1), 96–107 (2003).
  • Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 55(1), 299–307 (1999).
  • Van Wyck DB. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin. Nephrol. 9(1 Suppl. 2), 21–24 (1989).
  • Sika M, Sinsakul MV, Niecestro RM, Chiang S. Prolonged use of ferric citrate (FC) as a phosphate binder reduces IV iron use in Pts with ESRD. Presented at: Renal Week. Denver, CO, USA, 16–21 November 2010 (Abstract SA-PO2946).
  • Sinsakul MV, Sika M, Koury M et al. Iron absorption with higher doses of ferric citrate in controlling serum phosphorus in ESRD patients. Presented at: National Kidney Foundation Meeting (2010) (Abstract).
  • Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 44(4), 661–671 (2004).
  • Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Association between serum bicarbonate and death in hemodialysis patients: is it better to be acidotic or alkalotic? Clin. J. Am. Soc. Nephrol. 1(1), 70–78 (2006).
  • Gennari FJ. Very low and high predialysis serum bicarbonate levels are risk factors for mortality: what are the appropriate interventions? Semin. Dial. 23(3), 253–257 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.